title: Effects of cilostazol on serum lipid concentrations and plasma fatty acid composition in type 2 diabetic patients with peripheral vascular disease.
abstract: Cilostazol is an anti-thrombotic and vasodilating agent, reported to have both anti-thrombotic and cerebral vasodilating effects. We investigated the effects of cilostazol on serum lipid concentrations and plasma fatty acid composition in type 2 diabetic patients with peripheral vascular disease. The serum concentrations of total cholesterol, triglycerides, high-density lipoprotein-cholesterol, lipoprotein (a), remnant-like particles-cholesterol, apolipoproteins, and plasma fatty acid composition were measured in 17 diabetic patients with peripheral vascular disease before and 1, 3, and 6 months after administration of cilostazol (200 mg/day). Serum triglyceride concentrations were significantly decreased after cilostazol (from 1.31+/-0.17 mmol/l to 0.86+/-0.07 mmol/l at 6 months, P<0.01). Plasma docosahexaenoic acid levels were significantly increased after cilostazol (4.11+/-0.26% to 4.94+/-0.26% at 6 months, P<0.01). Our findings show that cilostazol can induce some beneficial changes in serum lipid profile and plasma fatty acid composition.
authors.affiliation: The Second Department of Internal Medicine, Hirosaki University School of Medicine, 5 Zaifu-tyo, Hirosaki City, Aomori, 036-8562, Japan. nnakamur-tym@umin.ac.jp
authors.forename: N
authors.initials: N
authors.lastname: Nakamura
authors.forename: T
authors.initials: T
authors.lastname: Hamazaki
authors.forename: H
authors.initials: H
authors.lastname: Johkaji
authors.forename: S
authors.initials: S
authors.lastname: Minami
authors.forename: K
authors.initials: K
authors.lastname: Yamazaki
authors.forename: A
authors.initials: A
authors.lastname: Satoh
authors.forename: S
authors.initials: S
authors.lastname: Sawazaki
authors.forename: M
authors.initials: M
authors.lastname: Urakaze
authors.forename: M
authors.initials: M
authors.lastname: Kobayashi
authors.forename: H
authors.initials: H
authors.lastname: Osawa
authors.forename: H
authors.initials: H
authors.lastname: Yamabe
authors.forename: K
authors.initials: K
authors.lastname: Okomura
mesh_terms: D000368:Aged; D001053:Apolipoproteins / Q000097:blood; D001161:Arteriosclerosis / Q000188:drug therapy / Q000378:metabolism; D001786:Blood Glucose / Q000378:metabolism; D000077407:Cilostazol; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000473:pathology*; D005215:Fasting; D005227:Fatty Acids / Q000097:blood*; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D015394:Molecular Structure; D016491:Peripheral Vascular Diseases / Q000378:metabolism*; D013777:Tetrazoles / Q000737:chemistry / Q000378:metabolism* / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000737:chemistry / Q000378:metabolism* / Q000627:therapeutic use
chemical_list: D001053:Apolipoproteins; D001786:Blood Glucose; D000077407:Cilostazol; D005227:Fatty Acids; D006442:Glycated Hemoglobin; D008055:Lipids; D013777:Tetrazoles; D014665:Vasodilator Agents